This study reports that aging substantially reduces the density of lymphatic vessels in the mouse heart and, in supporting human spatial transcriptomic data, in the human left ventricle. The loss begins at roughly 16 months in mice, before the onset of cardiomyocyte hypertrophy and fibrosis, and is accompanied by immune cell accumulation, fibrinogen and amyloid deposition, myocardial edema, and diastolic dysfunction. Experimentally destroying cardiac lymphatics in young mice reproduces much of this phenotype, establishing causality rather than mere association. Mechanistically, the authors identify the nuclear isoform of interleukin-33 as a driver of lymphatic endothelial cell death, induced by T-cell-derived interferon gamma acting through JAK, STAT1, and TFAP2A. Restoring VEGFC or silencing Il33 in aged hearts partially rebuilt lymphatic density and reduced macrophage accumulation, but notably failed to correct diastolic dysfunction.
The heart has a drainage system, and almost nobody studies it. While thousands of papers have examined how blood vessels fail with age, the lymphatic network that clears fluid, proteins, immune cells, and metabolic debris out of heart muscle has been largely ignored. This paper makes the case that this neglect was a mistake.
The big idea is a sequence. Working in C57BL/6 mice, the Frankfurt and Helsinki groups tracked cardiac lymphatic vessels across the lifespan and found that density collapses starting around 16 months of age, equivalent to roughly middle age in a mouse. Crucially, this decline happens before the structural damage that cardiologists usually measure. Fibrosis does not become substantial until 20 months. Cardiomyocyte enlargement shows up at 18 months. The lymphatic loss comes first, and what follows it is a cascade of accumulation: macrophages, T cells, neutrophils, dendritic cells, plasma proteins leaking into tissue, amyloid deposits, and water. The heart becomes waterlogged and inflamed, and its ability to relax between beats declines.
Correlation is cheap in aging biology, so the authors did the harder experiment. They took young mice and selectively destroyed their cardiac lymphatics, using two independent methods. Within one to two months, those young hearts began reproducing features of old hearts: macrophage buildup, fibrinogen accumulation, and measurable diastolic dysfunction. The pumping function stayed normal. This is a meaningful result. It suggests that lymphatic failure is not a bystander effect of aging but one of its causes, at least for the relaxation problem that underlies the most common form of heart failure in older people.
The mechanism turns out to involve an unusual version of a familiar molecule. Interleukin-33 normally acts as a secreted signal, but it also has a nuclear form that stays inside the cell and regulates chromatin. The nuclear form accumulates in aging lymphatic vessels, and when the researchers forced human lymphatic cells to express it, those cells stopped dividing and started dying. Upstream, interferon gamma released by T cells that cluster around lymphatic vessels in old hearts appears to drive this. The protective counterweight, VEGFC, declines with age.
Restoring VEGFC in 18-month-old mice rebuilt lymphatic density and cut macrophage accumulation by roughly a third. It did not improve diastolic function. That negative result matters more than the positive ones for anyone thinking about therapy. Eight weeks of partial structural repair in an already-damaged heart was not enough to restore mechanical performance, which suggests either that the intervention came too late, ran too briefly, or that lymphatic density is only one of several contributors to stiffness.
What this study genuinely establishes is a new target and a new timeline. The intervention window appears to open in middle age, well before symptoms. What it does not establish is that anything available today moves that target in humans.
Actionable Insights
There is no supplement, drug, or protocol in this paper that a person can act on today. It is a mouse and cell-culture study with no human intervention arm.
What it does provide is a timing argument. Lymphatic decline in mice began at roughly 16 of 22 months studied, which is proportionally equivalent to human middle age, and it preceded fibrosis and heart enlargement by four months or more. Prevention logic therefore favors acting before diastolic stiffness appears, not after.
On magnitude: the age-related loss of cardiac lymphatic vessels was very large, with standardized effect sizes between 1.6 and 4.3 depending on the measure. For context, an effect size of 0.8 is conventionally called large. Put differently, old and young mice barely overlap on this measure. By contrast, the functional consequence was modest. Diastolic dysfunction in old mice had an effect size of about 0.85, and the measured change was roughly 9 percent.
The only lifestyle lever the authors cite is exercise, based on separate prior work suggesting exercise promotes cardiac lymphatic growth. That remains a reasonable inference, not a finding of this paper.
Context and Source
Open Access Paper: Age-associated loss of lymphatic vessels promotes cardiac inflammation
Institutions: Institute for Cardiovascular Regeneration, Goethe University Frankfurt, with the German Center for Cardiovascular Research, the Cardiopulmonary Institute, the Max Planck Institute for Heart and Lung Research in Bad Nauheim, and the Technical University of Munich in Germany; the Translational Cancer Medicine Program at the University of Helsinki and the Wihuri Research Institute in Finland; and the University of Vienna in Austria.
Countries: Germany, Finland, Austria
Journal: Nature Cardiovascular Research, published online 15 September 2026.
Impact evaluation: The impact score of this journal is 12.6, evaluated against a typical high-end range of 0–60+ for top general science, therefore this is a High impact journal.